{"id":"W4220682552","doi":"10.1158/1538-7445.sabcs21-p1-18-11","title":"Abstract P1-18-11: Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without prior chemotherapy (CT) in the MONALEESA-3 (ML-3) trial","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Internal medicine; Adjuvant; Population; Cancer; Breast cancer; Fulvestrant; Placebo; Oncology; Nuclear medicine; Tamoxifen; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00193845,0.0008046305,0.002241335,0.0003114523,0.0002180705,0.0011014,0.00063075,0.0007707896,0.005484406],"category_scores_gemma":[0.001553697,0.0002722294,0.004279567,0.00040856,0.0004034935,0.0007457876,0.0005448693,0.002012714,0.0005936173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006204867,"about_ca_system_score_gemma":0.0007362289,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004389288,"about_ca_topic_score_gemma":0.001312891,"domain_scores_codex":[0.9990051,0.0004806455,0.00005891448,0.0002321286,0.00008767591,0.0001355354],"domain_scores_gemma":[0.9990871,0.0002954976,0.0002361786,0.0001137487,0.00004247322,0.0002249472],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8655481,0.002241041,0.05329789,0.001237956,0.01390418,0.0003545897,0.0001504763,0.002345642,0.01109884,0.0003206062,0.005510338,0.04399042],"study_design_scores_gemma":[0.3942894,0.1877083,0.3476771,0.0003516509,0.0334746,0.001661901,0.000457086,0.00950718,0.00839416,0.002988844,0.01332451,0.0001651373],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891868,0.003502219,0.0005545657,0.0005634359,0.00008310505,0.000462191,0.004000208,0.00004993829,0.001597436],"genre_scores_gemma":[0.9919012,0.0006167556,0.0004078479,0.0005168571,0.0001219731,0.0005772076,0.004110774,0.00002599933,0.001721444],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005484406,"threshold_uncertainty_score":0.01834714,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05174704060359159,"score_gpt":0.3807966049095876,"score_spread":0.329049564305996,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}